Celltrion and Teva Pharmaceutical announced that the FDA has approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin (trastuzumab)...
The European Commission has granted EU marketing authorisation in 28 countries for Vargatef (nintedanib), from Boehringer, in combination with docetaxel...
This is a prospective randomized phase II clinical trial where patients who are receiving enzalutamide in the pre-chemotherapy space are...
BMS has announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care...